|
|
|
Volumn 39, Issue 6, 2001, Pages 232-238
|
|
Anti-obesity drugs: Use, mechanisms and clinical importance
a
|
|
Author keywords
Anti obesity drugs; Fat replacer; Fat substitutes; Gastrointestinal hormones; Obesity
|
|
Indexed keywords
ACARBOSE;
ALPHA GLUCOSIDASE INHIBITOR;
AMPHETAMINE DERIVATIVE;
ANOREXIGENIC AGENT;
ANTIOBESITY AGENT;
BETA 3 ADRENERGIC RECEPTOR;
BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT;
CARBOHYDRATE;
CHOLECYSTOKININ;
DEXFENFLURAMINE;
FAT;
FENFLURAMINE;
FLUOXETIN;
GALANIN;
LEPTIN;
MITIGOL;
NEUROPEPTIDE Y;
NEUROPEPTIDE Y RECEPTOR ANTAGONIST;
NORADRENALIN UPTAKE INHIBITOR;
PAROXETIN;
PHENTERMINE;
PHENYLPROPANOLAMINE;
PLACEBO;
PROTEIN;
SEROTONIN UPTAKE INHIBITOR;
SERTRALIN;
SIBUTRAMINE;
SUCROSE POLYESTER;
TETRAHYDROLIPSTATIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ABSORPTION;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST;
COST BENEFIT ANALYSIS;
DEVELOPED COUNTRY;
DIARRHEA;
DIET THERAPY;
DRUG EFFICACY;
ENERGY EXPENDITURE;
HEALTH HAZARD;
HORMONE SYNTHESIS;
HUMAN;
HUNGER;
HYPERTENSION;
LOW FAT DIET;
MEDICAL INFORMATION;
NUTRIENT;
OBESITY;
PHYSICIAN;
PREVALENCE;
PULMONARY HYPERTENSION;
RISK BENEFIT ANALYSIS;
SATIETY;
SIDE EFFECT;
SURGERY;
TREATMENT INDICATION;
XEROSTOMIA;
ANTI-OBESITY AGENTS;
APPETITE DEPRESSANTS;
COST-BENEFIT ANALYSIS;
ENERGY METABOLISM;
HUMANS;
OBESITY;
|
|
EID: 0034991723
PISSN: 09461965
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (18)
|
